Articles tagged with Cancer Cells
Researchers studied PTPRK's role in colorectal cancer, finding it acts as a tumour suppressor by regulating cell adhesion and growth factor signalling. The protein also promotes intestinal repair, with mice lacking PTPRK showing impaired wound-healing and increased susceptibility to damage.
Researchers have developed a new technique called burst sine wave electroporation (B-SWE) that can disrupt the blood-brain barrier around brain tumors without causing significant damage to healthy tissue. This method shows promise for treating aggressive brain cancers like glioblastoma, which currently have limited treatment options.
Researchers have designed a novel Co-STAR receptor that combines genetic components of four types of immune cells to recognize and fight cancer cells. In laboratory studies, the Co-STAR receptor induced a sustained anti-tumor response against human cancer cells, leading to long-lasting remissions in mouse models.
Researchers at the University of Notre Dame have developed a wireless LED device that can be implanted to treat deep-seated cancers. The device, combined with a light-sensitive dye, destroys cancer cells and triggers an immune response against them.
A team of Penn State researchers has created a modular genetic circuit that turns cancer cells into a 'Trojan horse,' causing them to self-destruct and kill nearby drug-resistant cancer cells. The circuit outsmarts resistance and eliminates it before the cancer cells can evolve.
Researchers found that bowel cancer cells can regulate their growth using genetic on-off switches, allowing them to maximize survival chances. The study also showed that DNA repair genes can be repeatedly created and repaired, acting as 'genetic switches' to control tumour growth or put the brakes back on.
A new Finnish study from University of Turku shows that already a 30-minute exercise can increase the proportion of tumor-killing white blood cells in the bloodstream of breast cancer patients. The amount of several different white blood cell types increased during exercise, with cytotoxic T cells and natural killer cells rising the most.
Researchers at Karolinska Institutet developed nanorobots that target and kill cancer cells using a 'kill switch' activated in low pH environments. The study achieved a 70% reduction in tumour growth in mice, paving the way for further investigation into its potential as a cancer treatment.
Researchers describe a new concept for an immune response against cancer and aging using senescent cell-derived vaccines. The vaccines aim to stimulate the immune system against cancer cells and slow down or reverse aging-related diseases.
Scientists have developed a new immunotherapy that can identify and fight cancer cells in patients with Merkel cell carcinoma. The treatment involves stimulating the immune system's T cells against specific elements of the virus involved in cancer formation.
Pristimerin selectively targets thioredoxin reductase, inducing apoptosis and inhibiting tumor growth. ROS accumulation triggers oxidative stress, leading to targeted destruction of cancer cells.
Researchers at Howard University have identified a new therapeutic strategy to combat prostate cancer by depleting amino acids. This depletion induces oxidative stress and DNA damage in cancer cells, making them more susceptible to treatment with DNA repair-targeted and immune checkpoint blockade therapies.
A new study found that nearly five percent of pancreatic adenocarcinoma patients achieve a pathological complete response (pCR) after treatment, leading to a 63% 5-year survival rate. The research highlights the importance of tailoring treatment based on factors such as chemotherapy regimens and radiation therapy.
Researchers at Brigham and Women's Hospital have developed a new nanomedicine therapy that delivers anticancer drugs to lung cancer cells and enhances the immune system's ability to fight cancer. The therapy shows promising results in cancer cells in the lab and in mouse lung tumor models, with potential applications for improving care...
Researchers found that metformin increases levels of microRNAs miR-2110 and miR-132-3p, targeting genes PIK3R3 and STMN1 to slow down cancer cell growth and division. This study provides new insights into metformin's molecular mechanisms and its potential as a preventive agent for reducing cancer growth.
The study reveals that the binding sites of USP28 and USP25 inhibitors are identical, leading to non-specific effects. Researchers now aim to develop precise inhibitors targeting either enzyme site to reduce side effects.
A team of researchers from Xi'an Jiaotong-Liverpool University has engineered a short sequence of artificial DNA to target the mutant protein p53-R175H, linked to lung, colorectal, and breast cancers. The new molecule, dp53m, inhibits cancer cell growth and increases sensitivity to chemotherapy agent cisplatin.
Researchers at The Hebrew University have developed a novel method combining nano informatics and machine learning to predict cancer cell behaviors with high accuracy. This innovative approach enables the rapid identification of cancer cell subpopulations with varying biological behaviors, facilitating personalized medicine.
Researchers at MUSC Hollings Cancer Center discover polyploid giant cancer cells can lead to disease recurrence after chemotherapy or radiotherapy. They found that targeting these 'monster cells' could prevent tumor relapse, and potential therapies like tamoxifen and statins may also be effective.
Researchers at Hollings Cancer Center have identified a promising therapeutic strategy to combat pancreatic cancer. By simultaneously blocking HSP70 and autophagy, the growth of pancreatic tumors can be slowed, offering new hope for treatment.
A study by Charité researchers found that yeast cells can compensate for aneuploidy by exchanging proteins faster. This mechanism could be used to tackle treatment-resistant tumors and fungal infections. The study identified a previously unknown compensation system based on Saccharomyces cerevisiae.
A study found that moderate-to-vigorous exercise bouts increased natural killer cells' ability to kill cancer cells and made them more susceptible to antibody therapy. This could hold promise for improving treatment outcomes for some forms of chronic lymphocytic leukemia. Further research is needed to confirm these findings.
Research reveals cell-in-cell phenomena are common in non-cancer cells, playing roles in development, homeostasis and stress response. The study argues against targeting cell-in-cell events for cancer therapy, opening new avenues for research in evolutionary biology, oncology and regenerative medicine.
Researchers at Ben-Gurion University have discovered a molecular mechanism that enables cancer cells to survive under glucose starvation. By targeting this pathway, they aim to develop a molecule that can block the survival of tumor cells while leaving healthy cells unaffected.
Researchers found a new pathway to cancer cell death led by the Schlafen11 (SLFN11) gene. This discovery could have implications for cancer treatment and patient outcomes.
Researchers have developed a new imaging technique that rapidly and accurately identifies cancerous tissues in breast samples. The method uses machine learning algorithms trained on hyperspectral dark-field microscopy data to pinpoint regions of invasive ductal carcinoma and invasive mucinous carcinoma.
Researchers discovered that aggressive cancer cells pull more strongly on the extracellular matrix than on themselves, while noninvasive cells pull more strongly on themselves. The study found that the interplay between these contractility modes determines a cell's potential for escape and tumor aggressiveness.
A late University of Virginia School of Medicine scientist's research on the SAS1B protein could lead to new cancer treatments for multiple cancers. The discovery has the potential to selectively target cancer cells while sparing healthy tissue.
Researchers found that SARS-CoV-2 spike protein interrupts p53-MDM2 interaction but does not bind with p53 protein in cancer cells. The study also shows that SARS-CoV-2 spike suppresses p53-dependent gene activation, leading to increased cell viability after chemotherapy exposure.
A team of researchers at Bar-Ilan University has developed a groundbreaking technology that enables direct measurement of the interaction between immune cells and cancer cells from a patient's biopsy. This innovation provides crucial insights into the patient's immune response, enabling tailored cancer treatment decisions.
Researchers at the University of Seville discovered Galectin-3's crucial role in brain tumour progression, finding its inhibition significantly reduces glioblastoma size and brain metastases. Inhibition promotes pro-inflammatory markers and reverses immunosuppressive biomarkers, leading to improved outcomes.
A new study published in JAMA Oncology highlights the importance of testing for measurable residual disease (MRD) in patients with acute myeloid leukemia (AML) undergoing bone marrow transplants. The researchers found that detecting MRD can help predict cancer recurrence and improve patient outcomes.
Researchers at Johns Hopkins Medicine have charted a molecular pathway that can lure cells down a hazardous path of duplicating their genome too many times, a hallmark of cancer cells. The findings reveal what goes wrong when a group of molecules and enzymes trigger the cell cycle, leading to cancer development.
Researchers at TUM have uncovered a mechanism by which tumor cells prevent the formation of immune responses, including cytotoxic T cells. This discovery provides rationales for new cancer immunotherapies and could enhance existing treatments.
Researchers identified elevated MALAT1 levels in various blood cancers, correlating with adverse outcomes. MALAT1 promotes cancer cell proliferation, migration, invasion, and metastasis through multiple mechanisms.
Researchers at the University of Surrey have developed a technique to study lipids in live cancer cells, one by cell. This breakthrough could lead to more targeted treatments and better understanding of how individual cells communicate with their neighbors.
A new study reveals that aspirin boosts certain aspects of the immune system to detect and target cancer cells, reducing cancer spread to lymph nodes. Aspirin also increases expression of a protein called CD80 on immune cells, enhancing their ability to alert other immune cells of tumor-associated proteins.
Researchers have discovered that rice bran-derived nanoparticles exhibit strong anticancer effects, selectively targeting cancer cells while sparing healthy tissue. The nanoparticles reduced tumor growth and inhibited metastatic cell growth in mice models.
Scientists have designed a synthetic antigen that can stimulate antibody production against cancer cells. The approach uses a natural protein called serum albumin to carry the antigen, reducing the need for bulky carriers and side effects.
Researchers at the University of Nottingham have created a world-first device that can image individual cells' stiffness, potentially catching cancer earlier. The technology uses Brillouin scattering to detect stiffness down to billionths of a meter and could replace traditional biopsies with non-invasive, single-cell imaging.
Researchers have developed a new treatment that uses tailored doses of anti-cancer drugs released directly into the surgical cavity to treat liver cancer. The approach has shown promise in reducing recurrence rates and minimizing chemotherapy side effects, with potential applications for other types of cancer.
Researchers identified how AML cells develop resistance to first-line treatments by up-regulating multiple signalling pathways. Targeting RAS family proteins shuts off this route, preventing cancer cell death.
Researchers developed a breakthrough test to assess the enzymatic activity of glutathione peroxidase 4 (GPX4), a pivotal regulator of ferroptosis. The assay accurately measures GPX4 activity and extends its utility beyond GPX4, allowing for precise evaluation of other enzymes involved in ferroptosis regulation.
Researchers at Tel Aviv University developed a novel therapeutic strategy using existing medications to inhibit bone metastasis in breast cancer patients. The combination of drugs improved survival rates and reduced bone metastases in animal models and human tissue samples.
A study published in Nature Genetics reveals early cell changes in healthy carriers of BRCA1 and BRCA2 gene mutations, suggesting a potential target for breast cancer prevention. The researchers created the world's largest catalogue of human breast cells, which may lead to the use of existing immunotherapy drugs as an early intervention.
Researchers at the University of Toronto have found that two enzymes, APOBEC3C and APOBEC3D, promote resistance to chemotherapy drug gemcitabine in pancreatic cancer cells. Removing these enzymes can kill cancer cells by stymieing DNA repair.
A new study suggests that tailored treatment can predict the response of breast cancer patients to chemotherapy, allowing for safe omission of extensive lymph node removal. The MARI protocol showed a 95% overall survival rate and 89% disease-free survival rate in patients who achieved pathological complete response.
Researchers have discovered a new immunotherapy approach to overcome resistant leukemia by targeting the mutated TP53 gene. Combining pharmacological therapies with genetically engineered CAR T-cells increases effectiveness against cancer cells, offering promising strategies for patients with resistant disease.
A UNIGE team has identified the mechanism of action of PARP inhibitors, used to treat breast and ovarian cancer. By blocking one activity while preserving another, these inhibitors can maintain toxic effects on cancer cells while sparing healthy cells.
Scientists synthesized major component of mucus and discovered that altering healthy cell mucins made them act more like cancer cells. Researchers created synthetic mucins to study their impact on cancer biology, finding a potential target for cancer treatments.
Cancer cells can adapt to low oxygen levels by increasing glycolysis, a process controlled by enzymes LDHA and GOT1. Inhibiting these enzymes could target hard-to-reach cancer cells without affecting healthy cells.
A research team at the University of Cologne has identified mechanisms governing drug response in small cell lung cancer. The study reveals that large populations of treatment-sensitive cells often hide numerous therapy-resistant cells that can multiply unchecked after successful treatment.
Researchers have deciphered trabectedin's precise mechanism of action, revealing its ability to induce persistent DNA breaks in cancer cells. This disruption of the transcription-coupled nucleotide excision repair (TC-NER) pathway leads to long-lasting DNA breaks that ultimately kill cancer cells.
Human type 2 innate lymphoid cells have been found to attack and kill cancer cells in human models, with the ability to be expanded and applied in larger numbers to overpower tumors. This breakthrough could lead to a new therapeutic approach using these cells as an 'off-the-shelf' product.
Researchers discovered that lung cancer cells can persist in the presence of cigarette smoke due to a protein pump called ABCG2, which clears damaging molecules from the cells. This mechanism could also contribute to resistance to pharmaceutical treatments in cancer cells.
Research reveals micro- and nanoplastics can persist in the human body for longer than previously thought, being passed on to newly formed cells during cell division. The study also suggests these tiny plastic particles may promote the spread of cancer by increasing tumor migration.
A study published in Cancer Research Communications reveals a potential genetic marker associated with better survival outcomes in patients with head and neck cancer. The researchers found that the presence of a specific genetic variant and higher expression of the GAN gene product gigaxonin may contribute to improved survival rates.
A new nanocarrier has been developed that can selectively release drugs in cancer cells through controlled endosomal escape. The approach exploits the unique enzymatic activity of cancer cells, allowing for targeted delivery and reduced harm to healthy cells.
Researchers have discovered a new way to target chemotherapy-resistant ovarian cancer cells by depriving them of cholesterol, leading to significant tumor growth reduction. The nanoparticles starve the cells of cholesterol, triggering cell death through oxidation of lipids in the cell membrane.
A recent study used AI trained on cell-to-cell communication networks to predict drug responsiveness in immunotherapy for cancer. The model demonstrated high accuracy in analyzing samples from 700 patients with four types of cancer, identifying key communication pathways related to responsiveness and resistance.